FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913304730> ?p ?o ?g. }

• W2913304730 endingPage "973" @default.
• W2913304730 startingPage "973" @default.
• W2913304730 abstract "Contusion spinal cord injury (SCI) is a major medical and socio-economic problem globally. The incidence of SCI is highest among young adults due to motor vehicle accidents, military or sports injuries, and violence (Selvarajah et al., 2014). The elderly and children are also at risk due to falls and accidents. SCI causes neurodegeneration, with profound loss of locomotor and sensory functions (Siddiqui et al., 2015). Pain and depression are also prevalent in a majority of SCI patients. Expenses for severe SCI are high: initial hospitalization, rehabilitation, and most likely the continuing need for a caregiver and medical care. SCI survivors with less severe injuries usually face lower but still hefty medical bills. However, people ≥ 50 years old with severe SCI may face medical expenses of over $1.8 million during their lifetimes. These injuries also affect spouses and family members, emotionally and financially, and most injuries jeopardize employment for those affected. In sum, SCI has a lifelong effect on many people; it represents a major challenge for successful health care management. Other than critical care management and rehabilitation, no current Food and Drug Administration-approved drug therapy exists for traumatic SCI (Siddiqui et al., 2015). Several pharmacological therapies, including methylprednisolone, have been investigated in SCI, without therapeutic success. SCI is divided into two distinct phases (primary and secondary). The primary injury (immediately after SCI) is the physical damage caused by a traumatic event. It cannot be restored. Secondary spinal cord injury is a response to the initial physical insult and results from mechanistic crosstalk between several deleterious pathways: neuroinflammation, redox, and excitotoxicity (Siddiqui et al., 2015). Secondary injury is therefore amenable to reversal and treatment. Spinal cord contusion at thoracic or cervical levels shows similar molecular mechanisms and responds to similar treatment strategies. Functional deficits in rats after SCI are evaluated mainly by “Basso Beattie Bresnahan” locomotor rating scale. The Basso Beattie Bresnahan rating scale includes with a 21-point scale to measure hind limb function at various time points after injury. The scale assesses several different categories, including limb movement and tail position, as described in our publications (Chou et al., 2011; Khan et al., 2018). A critical examination of SCI pathobiology, its signaling mechanisms, and results from our initial studies indicate a disturbed nitric oxide (NO) metabolome as shown in Figure 1. Under physiological condition, nitric oxide synthase (NOS)-derived NO reacts with Glutathione in presence of oxygen and forms S-nitrosoglutathione (GSNO). After SCI (pathological condition), calcium dysregulation-induced excitotoxicity mechanisms are responsible for producing deleterious neuronal nitric oxide synthase (nNOS)-dependent peroxynitrite and activating calpain (Figures 1 and 2). These mechanisms cause lesions, neurodegeneration, pain sensitivity and functional deficits following SCI (Chou et al., 2011; Khan et al., 2018). Our publications (Chou et al., 2011; Khan et al., 2016, 2018) in SCI/traumatic brain injury show that these deleterious mechanisms are effectively down regulated by GSNO (an endogenous component of the human brain/body), leading to neuroprotection, improved pain sensitivity and functional recovery after SCI (Chou et al., 2011; Khan et al., 2018) and traumatic brain injury (Khan et al., 2016). GSNO invokes its effect mainly via S-nitrosylation, a reversible secondary modification of cysteines, leading to altered activity of S-nitrosylated enzymes such as NOS, calpains, nuclear factor-kappa B, hypoxia-inducible factor 1α, signal transducer and activator of transcription 3, and others. The degree of S-nitrosylation is reduced in many of neurodegenerative diseases due to increased peroxynitrite formation and thus decreased bioavailability of NO for GSNO biosynthesis.Figure 1: Schematic showing metabolism of NOS-derived NO under physiological vs. pathological condition.NOS-derived NO slowly reacts with GSH in presence of oxygen and forms GSNO under physiological condition. GSNO invokes its signaling via the mechanism of S-nitrosylation (adding NO moiety to sulfhydryl group) of proteins/enzymes in a regulated fashion. In contrast, in oxidative (pathological) environment, NO instantaneously reacts with superoxide forming peroxynitrite. Peroxynitrite, via nitration of tyrosine residue, forms 3-nitrotyrosine adduct of proteins/enzymes thus altering their functions. Peroxynitrite also oxidizes cysteine residue of proteins/enzymes rendering them inactive. NOS: Nitric oxide synthase; NO: nitric oxide; O2 – : superoxide; GSH: glutathione; GSNO: S-nitrosoglutathione; GSSG: oxidized glutathione; NH3: ammonia; GSNOR: S-nitrosoglutathione reductase; P-S-H: cysteine-protein; P-S-NO: S-nitrosoprotein; ONOO–: peroxynitrite; P-Tyr: tyrosine-protein; P-Tyr-NO2: nitrated-tyrosine protein; P-S(O)n-H: oxidized protein (where n represents number of oxygen atom ranging from 1 to 3).Figure 2: Schematic showing events involved in nNOS/peroxynitrite/calpain system vs. GSNO-mediated mechanisms under SCI.NO released from nNOS mediates physiological signaling events by reacting with GSH to generate GSNO. nNOS activation is mediated by NMDAR-induced Ca2+ influx and activation via phosphorylation of Serine1412, and denitrosylation of cysteine331. SCI induces sustained Ca2+ influx, activation of NMDAR, and dysregulation of nNOS. Consequent increase in superoxide (O2 –) and depletion of GSH result in decreased GSNO biosynthesis and increased peroxynitrite formation, thus causing a sustained and prolonged activation of nNOS and calpains, leading to sustained nitro-oxidative stress, neurodegeneration, pain pathology and functional deficits. This deleterious nNOS/peroxynitrite/calpain system is down regulated by exogenously-treated or endogenously-produced (inhibiting GSNOR by N6022) GSNO via S-nitrosylation of specific cysteines of nNOS and calpains, leading to neuroprotection, improved pain sensitivity and optimal functional recovery. While arrows indicate increasing the activity, expression or levels, horizontal (cross) lines indicate inhibiting or decreasing the activity, expression or levels. NO: Nitric oxide; nNOS: neuronal nitric oxide synthase; GSH: glutathione; GSNO: S-nitrosoglutathione; NMDAR: N-methyl-D-aspartate receptor; Ca2+: calcium ion; SCI: spinal cord injury; O2 –: superoxide; GSNOR: S-nitrosoglutathione reductase; -SNO: S-nitroso; N6022: GSNO reductase inhibitor( 3-(5-(4-(1H-imidazol-1-yl) phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl) propanoic acid)); NR1: Anti-NMDA Receptor 1; NR2: Anti-NMDA Receptor 2; PSD-95: postsynaptic density 95; 3-NT: 3-nitrotyrosine.Increased levels of neuronal peroxynitrite are involved in SCI secondary injury, causing nitro-oxidative stress and neuronal cell death (Bao and Liu, 2003). Peroxynitrite is formed by a diffusion limited reaction between NO and superoxide when they are simultaneously and instantaneously produced in the same compartment by aberrant nNOS activity. Interestingly, peroxynitrite is also responsible for the aberrant activity of nNOS because peroxynitrite oxidizes cysteines of the zinc thiolate cluster of NOS. Peroxynitrite also oxidizes and depletes tetrahydrobiopterin, a cofactor required for NOS activity, which also contributes to the aberrant activity and uncoupling of nNOS. Furthermore, Peroxynitrite causes a sustained activation of calpains via 3-nitrotyrosine (3-NT) formation (Khan et al., 2016), leading to neurodegeneration and functional deficits (Khan et al., 2011, 2016). In SCI, the observed increased levels of 3-NT, a peroxynitrite adduct of tyrosine residue, suggest its pathological role in SCI (Khan et al., 2018). Inhibition of nNOS activity following SCI has been shown to provide some degree of neuroprotection, and nNOS KO mice show improved recovery after SCI (Farooque et al., 2001), indicating a deleterious role of nNOS activity in SCI and that nNOS-based therapy for SCI is a logical approach. Furthermore, 3-NT positive neurons are more sensitive to increased calpain activity and neuronal cell death (Rameau et al., 2003). Increased calpain activity was indicated by specific SBDP145 kDa alpha II spectrin degradation product, without changes in expression levels of either calpains in SCI. These results indicate that increased peroxynitrite enhances calpain activity. As with GSNO, calpain inhibitors inhibit calpain activity. However, calpain inhibitors had no effect on the activation of nNOS and the production of peroxynitrite, supporting our hypothesis that GSNO invokes its effects via the inhibition of both nNOS and calpain, thus decreasing peroxynitrite, reducing neurodegeneration and showing greater and accelerated efficacy. Reversible down regulation of nNOS as well as calpain activity, such as via GSNO/S-nitrosylation, is preferred because it maintains the required physiological activity of calpains/nNOS. The pathological roles of other NOS enzymes (inducible and endothelial) in contusion SCI’s neurodegeneration and pain are not well understood. In addition to GSNO’s anti-neurodegenerative, anti-inflammatory and anti-oxidant effects, it also protects against endothelial dysfunction and increases vessel density via angiogenesis (Khan et al., 2015). In clinical settings of SCI, GSNO is of great relevance due to its vasodilatory, cerebral blood flow-enhancing and blood-brain barrier-protecting activities (Khan et al., 2011). However, the mechanism of GSNO’s effect on pain is not clearly understood because the mechanisms underlying neuropathic pain are multifactorial and complex. Among them, peroxynitrite originating from N-Methyl-D-aspartic acid receptor activation and NOS activity (Tanabe et al., 2009) are prominent causes of neuropathic pain following nerve injury. N-Methyl-D-aspartic acid receptor activation and calcium dysregulation are also associated with nNOS activation and peroxynitrite formation in SCI. Recently, the mechanism of S-nitrosylation/GSNO has been reported to reduce pain sensitivity (Shunmugavel et al., 2012). Therefore, S-nitrosylation/GSNO-mediated inhibition of peroxynitrite production, leading to reduced neurodegeneration and demyelination, may be responsible for alleviating pain sensitivity. GSNO is a natural component of the human body, and its exogenous increase by administration or by inhibiting GSNO reductase is not known to be associated with any adverse effects. GSNO reductase is the major GSNO-degrading enzyme and thus GSNO reductase KO mice store GSNO in excess. Conclusively, GSNO blocked the production of peroxynitrite by inhibiting aberrant nNOS activity, reduced calpain activity, improved locomotor rating scale (Basso Beattie Bresnahan), and mitigated mechanical allodynia (Figure 2). These findings support the efficacy of GSNO in ameliorating SCI and provide a rationale to evaluate GSNO-mediated signaling events in SCI. Furthermore, the therapeutic efficacy of GSNO may be amenable to manipulation by exogenous vs. endogenous (using N6022) and single dose vs. multiple doses. GSNO also shows similar efficacy in an animal model of lumbar spinal stenosis/compression (Shunmugavel et al., 2012), supporting its therapeutic potential for SCI therapy. Due to its translational potential, clinical relevance, and non-toxic nature, testing the efficacy of low dose GSNO may lead to human SCI therapy. This work was supported by the grants from South Carolina Spinal Cord Injury Research Fund (No.CIRF2017 I-01) and VA award (No.RX2090). Additional file:Open peer review report 1." @default.
• W2913304730 created "2019-02-21" @default.
• W2913304730 creator A5032747758 @default.
• W2913304730 creator A5044613830 @default.
• W2913304730 date "2019-01-01" @default.
• W2913304730 modified "2023-10-14" @default.
• W2913304730 title "Therapeutic exploitation of the S-nitrosoglutathione/S-nitrosylation mechanism for the treatment of contusion spinal cord injury" @default.
• W2913304730 cites W1591103981 @default.
• W2913304730 cites W1893745485 @default.
• W2913304730 cites W1968793573 @default.
• W2913304730 cites W1985615683 @default.
• W2913304730 cites W1997358558 @default.
• W2913304730 cites W2035844890 @default.
• W2913304730 cites W2078534222 @default.
• W2913304730 cites W2082726687 @default.
• W2913304730 cites W2109194131 @default.
• W2913304730 cites W2150186313 @default.
• W2913304730 cites W2175688109 @default.
• W2913304730 cites W2886193721 @default.
• W2913304730 doi "https://doi.org/10.4103/1673-5374.250572" @default.
• W2913304730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6404493" @default.
• W2913304730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30762004" @default.
• W2913304730 hasPublicationYear "2019" @default.
• W2913304730 type Work @default.
• W2913304730 sameAs 2913304730 @default.
• W2913304730 citedByCount "5" @default.
• W2913304730 countsByYear W29133047302020 @default.
• W2913304730 countsByYear W29133047302021 @default.
• W2913304730 crossrefType "journal-article" @default.
• W2913304730 hasAuthorship W2913304730A5032747758 @default.
• W2913304730 hasAuthorship W2913304730A5044613830 @default.
• W2913304730 hasBestOaLocation W29133047301 @default.
• W2913304730 hasConcept C111472728 @default.
• W2913304730 hasConcept C118552586 @default.
• W2913304730 hasConcept C138885662 @default.
• W2913304730 hasConcept C181199279 @default.
• W2913304730 hasConcept C185592680 @default.
• W2913304730 hasConcept C2776015013 @default.
• W2913304730 hasConcept C2777553025 @default.
• W2913304730 hasConcept C2778334475 @default.
• W2913304730 hasConcept C2779201268 @default.
• W2913304730 hasConcept C2780775167 @default.
• W2913304730 hasConcept C538909803 @default.
• W2913304730 hasConcept C55493867 @default.
• W2913304730 hasConcept C71924100 @default.
• W2913304730 hasConcept C89611455 @default.
• W2913304730 hasConceptScore W2913304730C111472728 @default.
• W2913304730 hasConceptScore W2913304730C118552586 @default.
• W2913304730 hasConceptScore W2913304730C138885662 @default.
• W2913304730 hasConceptScore W2913304730C181199279 @default.
• W2913304730 hasConceptScore W2913304730C185592680 @default.
• W2913304730 hasConceptScore W2913304730C2776015013 @default.
• W2913304730 hasConceptScore W2913304730C2777553025 @default.
• W2913304730 hasConceptScore W2913304730C2778334475 @default.
• W2913304730 hasConceptScore W2913304730C2779201268 @default.
• W2913304730 hasConceptScore W2913304730C2780775167 @default.
• W2913304730 hasConceptScore W2913304730C538909803 @default.
• W2913304730 hasConceptScore W2913304730C55493867 @default.
• W2913304730 hasConceptScore W2913304730C71924100 @default.
• W2913304730 hasConceptScore W2913304730C89611455 @default.
• W2913304730 hasIssue "6" @default.
• W2913304730 hasLocation W29133047301 @default.
• W2913304730 hasLocation W29133047302 @default.
• W2913304730 hasLocation W29133047303 @default.
• W2913304730 hasLocation W29133047304 @default.
• W2913304730 hasOpenAccess W2913304730 @default.
• W2913304730 hasPrimaryLocation W29133047301 @default.
• W2913304730 hasRelatedWork W2022008878 @default.
• W2913304730 hasRelatedWork W2055687195 @default.
• W2913304730 hasRelatedWork W2276127939 @default.
• W2913304730 hasRelatedWork W2382449071 @default.
• W2913304730 hasRelatedWork W2386002113 @default.
• W2913304730 hasRelatedWork W2810310896 @default.
• W2913304730 hasRelatedWork W2898888137 @default.
• W2913304730 hasRelatedWork W2982258584 @default.
• W2913304730 hasRelatedWork W3034714285 @default.
• W2913304730 hasRelatedWork W4229032405 @default.
• W2913304730 hasVolume "14" @default.
• W2913304730 isParatext "false" @default.
• W2913304730 isRetracted "false" @default.
• W2913304730 magId "2913304730" @default.
• W2913304730 workType "article" @default.